[1] 中华医学会血液学分会. 骨髓增生异常综合征中国诊断与治疗指南(2019年版)[J]. 中华血液学杂志,2019,40(2):89-97.
[2] CAZZOLA M. Myelodysplastic syndromes[J]. N Engl J Med,2020, 383(14):1358-1374.
[3] YE X,CHEN D,ZHENG Y,et al. The incidence,risk factors,and survival of acute myeloid leukemia secondary to myelodysplastic syndrome:a population-based study[J]. Hematol Oncol,2019,37(4):438-446.
[4] KHOURY J D,SOLARY E,ABLA O,et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours:myeloidand histiocytic/dendritic neoplasms[J]. Leukemia,2022,36(7):1703-1719.
[5] FENAUX P,HAASE D,et al.Myelodysplastic syndromes:ESMO Clinical Practice Guidelines for diagnosis,treatment and follow-up[J]. Ann Oncol,2021,32(2):142-156.
[6] 商丽梅,陈惠娟,刘月,等. 骨髓增生异常综合征进展的伴骨髓增生异常相关改变急性髓系白血病患者的生存及预后分析[J]. 中国实验血液学杂志,2024,32 (2):347-354.
[7] YOUNG N S. Aplastic anemia[J]. N Engl J Med,2018,379(17):1643-1656.
[8] VOTAVOVA H,BELICKOVA M. Hypoplastic myelodysplastic syndrome and acquired aplastic anemia:immune-mediated bone marrow failure syndromes (Review)[J]. Int J Oncol,2022,60(1):7.
[9] FATTIZZO B,SERPENTI F,BARCELLINI W,et al. Hypoplastic myelodysplastic syndromes:just an overlap syndrome?[J].Cancers (Basel),2021,13(1):132.
[10] 施均,郑以州. 再生障碍性贫血与低增生性骨髓增生异常综合征鉴别诊断思路[J]. 中华血液学杂志,2013,34(10):910-912.
[11] LEW J L,FENDERSON J L,CARMICHAEL M G. Next-generation gene sequencing differentiates hypoplastic myelodysplastic syndrome from aplastic anemia[J]. Hawaii J Med Public Health,2017, 76( 11 Suppl2):10-12.
[12] DUNN W G,MCLOUGHLIN M A, VASSILIOU G S. Clonal hemato-poiesis and hematological malignancy[J]. J Clin Invest,2024,134(19):e180065.
[13] SCHWIND S,JENTZSCH M,KUBASCH A S,et al. Myelodysplastic syndromes:biological and therapeutic consequences of the evolving molecular aberrations landscape[J]. Neoplasia,2021,23(11): 1101-1109.
[14] AUERBACH S,PUKA B,GOLLA U,et al. Recent advances towards the understanding of secondary acute myeloid leukemia progression[J].Life (Basel),2024,14(3):309.
[15] NILSSON C,HULEG?魡RDH E,GARELIUS H,et al. Secondary acute myeloid leukemia and the role of allogeneic stem cell transplantation in a population-based setting[J]. Biol Blood Marrow Transplant,2019,25(9):1770-1778.
[16] SENGSAYADETH S,GATWOOD K S,BOUMENDIL A,et al. Conditioning intensity in secondary AML with prior myelodysplastic syndrome/myeloproliferative disorders:an EBMT ALWP study[J].Blood Adv,2018,2(16):2127-2135.
[17] 中华医学会血液学分会白血病淋巴瘤学组. 成人急性髓系白血病(非急性早幼粒细胞白血病)中国诊疗指南(2023年版)[J]. 中华血液学杂志,2023,44(9):705-712.
[18] 韩秀蕊,杨娣娣,赵园,等. 281例骨髓增生异常综合征患者染色体核型分析及临床意义的研究[J]. 现代检验医学杂志,2015,30 (4):91-92,95.
[19] 徐娜娜,吴涛,寇明坤,白海.ASXL1基因突变在急性髓系白血病中的研究进展[J].内科理论与实践,2022,17(4):353-355.
[20] CARBUCCIA N,TROUPLIN V,GELSI-BOYER V V,et al. Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias[J]. Leukemia,2010,24(2):469-473.
[21] KAKOSAIOU K,PANITSAS F,DARAKI A,et al. ASXL1 mutations in AML are associated with specific clinical and cytogenetic characteristics[J]. Leuk Lymphoma,2018,59(10):2439-2446.
[22] 冯砚平,王楠,王伟佳. FLT3突变急性髓系白血病的临床特点及其伴随突变对预后的影响[J]. 检验医学与临床,2022,19(11):1481-1485.
[23] 张梅香,史文芝,刘建新,等. MLL-AF6融合基因阳性急性髓系白血病的临床特征及预后[J]. 北京大学学报(医学版),2021,53 (5):915-920.